Mission Bio · Tapestri Platform
Gene Expression
Reference Target Portfolio
Reference Target Portfolio
Single-Cell Multi-Omics · Targeted Transcriptomics · 2026
23 Panels
4 Disease Categories
195 – 306 Targets / Group
7 Functional Categories Each
| Disease / Application | Unique Genes | Func. Categories | Functional Categories (genes per category) | Flyer |
|---|---|---|---|---|
| Hematologic Malignancies 6 panels | ||||
|
Acute Lymphoblastic Leukemia (ALL)
B-ALL · T-ALL · Ph+ ALL
|
242 | 7 | Driver / Ph / Ph-like Fusions 52Lymphoid Lineage / Subtype 50CAR-T Antigens / Surface 42Immune Evasion / MRD 40T-ALL / NOTCH1 Axis 40Cell Cycle / Apoptosis 24Epigenetic / Splicing 20 | View ↗ |
|
AML / MDS
AML · MDS · MPN
|
291 | 7 | Driver Mutations & Oncogenic SignalingCell State / Differentiation HierarchyProliferation / Cell CycleApoptosis / Therapy ResistanceImmune MicroenvironmentCytokine / Niche SignalingEpigenetic / Splicing / DNA Repair | View ↗ |
|
Myeloproliferative Neoplasms (MPN)
ET · PV · MF
|
243 | 7 | JAK-STAT / Driver 52Cytokine / Fibrosis 48HSC / Myeloid Differentiation 52Immune / Inflammation 40Resistance / BCL-2 32Cell Cycle 18Epigenetic / CHIP 20 | View ↗ |
|
Multiple Myeloma
Newly Diagnosed MM · RRMM · High-Risk (del17p / t(4;14))
|
245 | 7 | Plasma Cell Identity & Drivers 64Bone Marrow Niche 46Immune Microenvironment 53Drug Resistance 41Proliferation / Cell Cycle 33Apoptosis / BCL-2 30DNA Damage / Epigenetics 34 | View ↗ |
|
Non-Hodgkin Lymphoma (NHL)
DLBCL (GCB / ABC) · Follicular Lymphoma · MCL
|
253 | 7 | B Cell Oncogenic Signaling 64Immune Microenvironment 60B Cell Identity & Differentiation 45Epigenetic / Chromatin 35Proliferation / Cell Cycle 32Apoptosis / Therapy Resistance 35DNA Damage / Genomic Stability 29 | View ↗ |
|
Multiple Sclerosis
RRMS · PPMS · SPMS
|
230 | 7 | T Cell / Autoimmune Pathways 52B Cell / Plasma Cell 38Microglia / CNS Innate 42Oligodendrocyte / Remyelination 42Astrocyte / Neuroinflammation 38Therapy Targets 28Cytokines / Complement 24 | View ↗ |
| Solid Tumors 12 panels | ||||
|
Bladder Cancer
NMIBC · MIBC · UC
|
256 | 7 | Driver / FGFR3 / PIK3CA 48Lineage / MIBC Subtypes 52Immune TME 52DDR / Cisplatin Sensitivity 32Stroma / EMT 38Cell Cycle 24Metabolism 19 | View ↗ |
|
Brain Cancer / Glioma
GBM · IDH-mutant Glioma · Pediatric GBM
|
239 | 7 | IDH / Driver Oncogenes 52Glioma Cell States 63Immune Microenvironment 52Proliferation / Cell Cycle 28Epigenetic / MGMT 28Invasion / Angiogenesis 28WHO Lineage / Stem Identity 30 | View ↗ |
|
Breast Cancer
HR+ · HER2+ · TNBC
|
290 | 7 | Hormone Receptor & HER2 61DNA Damage / HRD 39Immune Microenvironment 59Stromal / Angiogenesis 44Proliferation / Cell Cycle 34AR / Metabolism 27Cell State / Lineage 36 | View ↗ |
|
Colorectal Cancer (CRC)
Colorectal Cancer · Solid Tumor · Multi-pathway
|
266 | 7 | Tumor Intrinsic SignalingCell State / DifferentiationProliferation / Cell CycleEMT / InvasionImmune MicroenvironmentStromal / AngiogenesisDNA Damage / Genomic Stability | View ↗ |
|
Endometrial Cancer
MSI-H · POLE-ultramutated · p53-mutant
|
232 | 7 | TCGA Molecular Subtypes / Driver 48MMR / POLE / TMB 42HER2 / PI3K Pathway 40Immune TME / Checkpoint 48Lineage / Histotype 36Stroma / EMT 28Cell Cycle 20 | View ↗ |
|
Hepatocellular Carcinoma (HCC)
HCC · Cholangiocarcinoma · Combined HCC-ICC
|
232 | 7 | Driver / CTNNB1 / TERT 52VEGF / Angiogenesis 38Immune TME 52Fibrotic Stroma / HSC 40Lineage / HCC Subtypes 38Cell Cycle 22Metabolism / Lipid 20 | View ↗ |
|
Head & Neck Cancer (HNSCC)
HPV+ Oropharynx · HPV− HNSCC · Oral Cavity
|
240 | 7 | Driver / EGFR / PI3K 52Squamous Lineage / Subtype 48Immune TME / Checkpoint 52HPV+ Biology 32Stroma / EMT 38Cell Cycle 24DDR / HRD 19 | View ↗ |
|
Melanoma
Cutaneous · Acral · Mucosal
|
251 | 7 | MAPK Driver Signaling 63Immune Microenvironment 66MAPKi Resistance 39MHC-I & Antigen Presentation 31Stromal / Angiogenesis 33Proliferation / Cell Cycle 30DNA Damage / UV Signature 38 | View ↗ |
|
Non-Small Cell Lung Cancer (NSCLC)
NSCLC · Adenocarcinoma · Squamous Cell
|
256 | 7 | Oncogenic Driver Signaling 67Immune Microenvironment 66Histotype Lineage 41Stromal / Angiogenesis 39Proliferation / Cell Cycle 31DNA Damage / HRD 30Metabolism / Stress 26 | View ↗ |
|
Ovarian Cancer
HGSOC · LGSC · Clear Cell
|
221 | 7 | Tumor Intrinsic Signaling 65Immune Microenvironment 61Ovarian Tumor Cell States 41Peritoneal Metastasis 39PARPi / Platinum Resistance 36Stromal / Angiogenesis 32Proliferation / DNA Repair 26 | View ↗ |
|
Pancreatic Cancer (PDAC)
PDAC · Acinar Cell Carcinoma · Resectable / Locally Advanced / Metastatic
|
205 | 7 | KRAS / RAS-Effector Signaling 68Desmoplastic Stroma 51Immune Microenvironment 58Tumor Cell States / Subtype 41DDR / HRD 35Metabolic Reprogramming 33EMT / Invasion 14 | View ↗ |
|
Prostate Cancer
Localized PCa · CRPC · CRPC-NE
|
283 | 7 | AR Pathway & Steroidogenesis 61DNA Damage / HRD 41Immune Microenvironment 55Bone Niche / Stroma 41Proliferation / Cell Cycle 33Lipid / Metabolism 33Cell State / PSMA 36 | View ↗ |
| Autoimmune / Neuroimmune 1 panel | ||||
|
Pediatric Rheumatology
JIA · pSLE · JDM
|
306 | 7 | Innate Immune Activation & IFN Signaling 64Adaptive Lymphocyte Programs 69Cytokine & JAK-STAT Signaling 61Stromal / Fibroblast & Tissue Remodeling 33Immune Regulation & Tolerance 42Complement & Autoantibody Biology 35Cell Activation / Co-stimulation & Trafficking 51 | View ↗ |
| Cross-Indication Applications 4 panels | ||||
|
CAR-T Cell Therapy
CD19 · BCMA · GD2
|
195 | 7 | CAR-T Product Identity & Phenotype 54Target Antigen on Tumor 39In Vivo Persistence & Fitness 40TME Resistance 35Manufacturing QC & Comparability 25Donor / Allogeneic Considerations 24CRS & ICANS Risk 23 | View ↗ |
|
Drug Resistance Mechanisms
Pan-cancer · Targeted therapy · Chemotherapy
|
252 | 7 | RTK & Bypass Signaling 59DNA Repair & Therapy Resistance 49Apoptosis & Survival Escape 30Lineage Plasticity & Switching 47Immune Checkpoint Resistance 43Metabolic & Microenvironmental 30Senescence & Ferroptosis 30 | View ↗ |
|
Immunotherapy (IO) Response
Pan-solid tumor · PD-1/PD-L1 / CTLA-4 / LAG-3 / TIM-3 / TIGIT · All ICI-approved indications
|
221 | 7 | T Cell Identity & Exhaustion 118Checkpoint Ligands & Antigen Presentation 40Myeloid & NK States 48TLS & B Cell Programs 31IFN Signaling & TIS Score 28DNA Damage / TMB / MSI 22Metabolic Immune Escape 28 | View ↗ |
|
Tumor Microenvironment (TME)
Pan-cancer TME profiling · Hot / Cold / Excluded tumors · All solid tumor indications
|
247 | 7 | Myeloid Cell States 86T & NK Lymphocyte States 65B Cell & TLS 29CAF Subtypes & Stroma 40Tumor Cell States & Plasticity 49Complement & Innate Sensing 22Angiogenesis & Lymphangiogenesis 25 | View ↗ |
ⓘ Gene counts reflect unique genes per panel. Per-category counts may sum to a higher
number as select genes appear in more than one functional category.